Status:
RECRUITING
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Collaborating Sponsors:
Centre Henri Becquerel
University Hospital, Caen
Conditions:
Waldenstrom's Disease
Waldenstrom Macroglobulinemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Waldenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. This chronic lymphoproliferative disorde...
Eligibility Criteria
Inclusion
- Patient with WM according to diagnostic criteria
- Patients with WM followed in one of the centre of North-Western region.
- Patients requiring first-line or subsequent-line therapy
- Patients agreement for giving informed consent.
- Social insurance system affiliation
Exclusion
- Patients with another chronic B-cell malignancy
- patients with other lymphoplasmacytic proliferations
- patients with marginal zone lymphoma.
- Patients with WM and histologic transformation
- Absence of informed consent
Key Trial Info
Start Date :
May 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04893564
Start Date
May 16 2022
End Date
July 1 2028
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France, 80480